NEWS
November 2, 2023
Gilboa Therapeutics Publishes Data in the Blood Journal Supplement of ASH 2023
Gilboa publishes it groundbreaking work on SolidT, a novel engineered cytotoxic T cells therpy, in the Blood journal supplement of ASH 2023.
SolidT exhibits increased specificity, reduced exhaustion, and controlled cytokine secretion, making it a promising advancement in the treatment of lymphoma. In a CD20+ Raji-Luc xenograft model, SolidT + rituximab demonstrated superior anti-tumor activity and prolonged survival compared to traditional treatments.
Read more here.
​
April 9, 2024
Gilboa Therapeutics Presents Pre-clinical Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors
Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the presentation of pre-clinical data at the annual meeting of the American Association for Cancer Research demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed, and establish immune memory to eliminate secondary tumors.
The presentation is entitled “A modified FcγRI expressing T cell (SolidT) exhibits profound anti-tumor activity followed by maturation into effector memory t cells that can be reactivated to kill a secondary tumor.” It will be presented as part of the Adoptive Cell Therapies 4 Session, Poster Section 1, between 1:30 and 5:00 PT on Tuesday, April 9.
Until now, treatment of solid tumors with autologous T-cell therapies, such as CAR-T, have been limited by T-cell exhaustion, toxicity, and immunosuppressive tumor microenvironments. Furthermore, each solid tumor target requires a unique CAR-T cell product. Gilboa’s SolidT technology overcomes these limitations by utilizing a novel, engineered antibody receptor whereby the SolidT cells are activated specifically against high antigen expressing tumor cells, while sparing normal cells with low expression of the same antigens. The SolidT cells are engineered to target tumor cells via coadministration with therapeutic monoclonal antibodies. This activation mechanism prevents premature exhaustion, while also reducing the risk of systemic cytokine-related toxicities. It also allows for a single manufacturing process to generate SolidT cells to be used across multiple tumor types.
The abstract can be viewed here.
The poster can be viewed here.
April 18, 2023
Gilboa Therapeutics Publishes and Presents Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors
Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating
non-clinical proof of concept for SolidT cells coadministered with therapeutic antibodies.
​
Cambridge, MA - April 18, 2023 - Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the publication of a scientific paper demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed. The paper was published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).
The company will be presenting its data in a poster at the AACR Annual Meeting on April 18 at 9AM ET in Section 22.
Click here to read more.
Read the full article here.
December 19, 2022
Gilboa Therapeutics has been recognized as one of the 33 healthcare and biotech start-ups investors expect to take off in 2023
Gilboa Therapeutics has been recognized by Insider Business as one of the 33 healthcare and biotech start-ups investors expect to take off in 2023. We are grateful for the support of our investors and look forward to continuing to make progress in the development of our SolidT therapy.
We can't wait to see what the future holds for Gilboa Therapeutics!
​
Read the full article here.
​
Gilboa Therapeutics is delighted to welcome Barry Labinger as CEO
Barry Labinger brings more than 30 years of experience in leadership roles in the biopharmaceutical industry, including both public and private companies.
We look forward to a successful journey together!
​